Dr. Amitabha Kar
Head, Department of Human Physiology, Kabi Nazrul Mahavidyalay, Sonamura, Sepahijala, Tripura, India

Dr. Partha Majumder
Former Head and Coordinator, Department of Applied Biotechnology and Bioinformatics, Sikkim Manipal University, Sikkim, India

Debraj Nandi
Territory Manager, Micro Labs Limited, Agartala, Tripura, India

Based on bioinformatics, a metabolomic analyses for atherosclerosis, diabetes, and obesity

Dr. Amitabha Kar, Dr. Partha Majumder and Debraj Nandi

Abstract
Insulin resistance associated with type 2 diabetes mellitus (T2DM), obesity, and atherosclerosis is a global health problem. A portfolio of abnormalities of metabolic and vascular homeostasis accompanies T2DM and obesity, which are believed to conspire to lead to accelerated atherosclerosis and premature death. The complexity of metabolic changes in the diseases presents challenges for a full understanding of the molecular pathways contributing to the development of these diseases. The recent advent of new technologies in this area termed "Metabolomics" may aid in comprehensive metabolic analysis of these diseases. Therefore, metabolomics has been extensively applied to the metabolites of T2DM, obesity, and atherosclerosis not only for the assessment of disease development and prognosis, but also for the biomarker discovery of disease diagnosis. Herein, we summarize the recent applications of metabolomics technology and the generated datasets in the metabolic profiling of these diseases, in particular, the applications of these technologies to these diseases at the cellular, animal models, and human disease levels. In addition, we also extensively discuss the mechanisms linking the metabolic profiling in insulin resistance, T2DM, obesity, and atherosclerosis, with a particular emphasis on potential roles of increased production of reactive oxygen species (ROS) and mitochondria dysfunctions.

Keywords: Metabolomics analysis, atherosclerosis, diabetes, obesity, metabolites

Introduction

The metabolome is the terminal product downstream from the genome, transcriptome, and proteome, and consists of the total complement of all the low-molecular-weight molecules (metabolites) in a cell, tissue, or organism [1, 2]. Metabolomics is well defined as a technology aiming to measure/profile metabolite changes present within a cell, tissue, or organism in response to a genetic alteration or pathophysiological stimuli [3, 4]. Downstream of transcriptional, posttranscriptional, translational, and posttranslational processes, metabolites serve as the most proximal reporters of alteration in the body/tissue/cells in response to a disease process. Measurement of time-related metabolic changes in animal models in response to genetic manipulation can be used to define the varying phenotypes observed [5]. In general, metabolomics methodologies fall into two distinct groups: untargeted metabolomics, an intended comprehensive analysis of all the measurable identities in a sample including chemical unknowns; and targeted metabolomics, the measurement of defined groups of chemically characterized and biochemically annotated metabolites. The results of targeted metabolomics studies have demonstrated both feasibility and flexibility across physiological, pathological, interventional, and epidemiological human studies. In addition to the identifications of metabolites in the process of disorders, metabolomics also has the groups of well-established web-based databases available. These databases have linked the identified metabolites or compounds with specific disorders and physiological characteristics and they also have well defined the biological pathways or genome, transcriptome and proteome underlining the change of metabolites. As a result, the new methodologies of metabolomics have provided invaluable tools for the examination of these interactions on a global scale, and offer an alternative means of investigation to that of some of the more reductionist molecular biology approaches.

Analytical approaches applied to identify changes in the concentrations and fluxes of endogenous metabolites include, but are not limited to, ^{1}H and ^{13}C nuclear magnetic resonance (^{1}H- and ^{13}C-NMR) spectroscopy, gas chromatography-mass spectrometry (GC-

Correspondence
Dr. Partha Majumder
Former Head and Coordinator, Department of Applied Biotechnology and Bioinformatics, Sikkim Manipal University, Sikkim, India

MS), gas chromatography-flame ionization detection (GC-FID), direct infusion-mass spectrometry (DI-MS), and liquid chromatography-mass spectrometry (LC-MS). Also, shows how metabolomic technology (MS) works and separates the molecules based on their different masses in a typical reaction. As an addition to other metabolomic databases listed in the tables, the spectral database includes almost all spectrometries applied in the metabolomics research. However, due to the wide range of metabolites and the dynamic nature of their concentrations within the cell, a complete analysis of the metabolome has thus far eluded description even when a range of analytical approaches have been employed [6]. In addition, metabolomics has been increasingly applied to the biomarker discovery of cardiovascular diseases, diabetes, and early changes of metabolites in obesity through metabolic profiling in patients with metabolic syndrome [7, 8, 9], MS-based metabolic profiling of acylcarnitines species in insulin resistance animal models [10], cellular lipid signaling [11], as well as profiling amino acids and acylcarnitines in obesity individuals [12]. Although various methodologies have been employed, two technologies have prevailed as the core methodologies of metabolite profiling: NMR [13] and MS, with the latter coupled to an array of separation techniques including GC and LC.

The integration of metabolomics with genomics, transcriptomics, and proteomics plays an important role in the research of systems biology. In many cases mRNA expression and protein levels are poorly correlated, and in certain cases they may be even more poorly correlated with phenotypes which are several steps "up-stream" of the flow of genetic information. Besides, transcriptomics studies can be the quite costly, in contrast, proteomic studies are relatively time consuming. Meanwhile, the application of metabolomics to a mouse model of disease can rapidly profile a range of tissues. This profiling would allow us to understand how one gene mutation affects metabolism in the blood plasma and multiple tissues such as white adipose tissue, fast- and slow- twitch skeletal muscle, and cardiac tissue. As result, an *in vivo* model can be built on systemic metabolism changes across the organism following a genetic modification [14], not all of those findings in transgenic models can be translated into the human diseases yet. In particular, recent progress has been made toward the understanding of the highlighted pathways of changed metabolite profiles in diseases. In this article, we focus to review the applications of metabolomics, and the changes of metabolites as well as the specific pathways underlining the pathophysiology in atherosclerosis, metabolism syndrome, and obesity.

Applications of metabolomics in atherosclerosis

Metabolomics has being applied to analyze atherosclerotic samples for biomarker discovery and circulating metabolite profiling that may play an important role as regulatory signals in the development of the disease. In order to identify differences in plasma metabolites of individuals with and without ischemia, Sabatine *et al.* [15] employed a MS-based technology in the study. The results showed that lactic acid and its metabolites, such as hypoxanthine, inosine, and alanine that are involve in skeletal muscle AMP catabolism increase after exercise stress test in both patients and healthy controls. In contrast, there was significant discordant regulation of multiple metabolites in patients with ischemia demonstrated by increased MET193 and MET221 and decreased plasma levels of γ-aminobutyric acid, MET288, oxaloacetate, citrulline, and argininosuccinate, which were caused by the preservation of citric acid cycle intermediates to defend ATP production in the myocardium. This metabolomics study exhibited a discovery of novel biomarkers of acute myocardial ischemia. In addition, pattern-recognition techniques were also applied to ^{1}H-NMR spectra of human serum. The study showed that the most influential factors for the development of severe atherosclerosis are increased metabolites of CH_2 chain (chemical shift ð1.26, ð1.3 and ð1.34 on 600 MHz ^{1}HNMR spectra) and CH_3 group (chemical shift ð86) produced from fatty acid side chains in lipid, in particular LDL and VLDL). In this study, investigators can correctly diagnose not only the presence, but also the severity, of angiographically-defined coronary heart disease with a specificity of >90% [16]. The similar serum metabolic profiles and chemical shift patterns were indicated in patients with high systolic blood pressure (SBP), demonstrating that there was a relationship between serum metabolic profiles and blood pressure, which in part was thought due to lipoprotein particle composition differences between the samples [17]. Taken together, these studies showed for the first time a technique capable of providing an accurate, noninvasive, and rapid diagnosis of coronary heart disease and hypertension, which can be used clinically either in population screening or effective targeting of treatments. However, some authors argued about the predictive power and specificity of ^{1}H-NMR methodology in the detection of coronary artery disease (CAD), stating that the analysis was dependent mainly on the major lipid regions of the spectra, and that many variables, including gender and drug treatment, affect lipid composition and are potential confounders [18].

Recently, investigators applied GC-MS fingerprinting to the plasma samples of patients with acute coronary syndrome in comparison with that of healthy controls for disease diagnosis with pattern recognition techniques. Interestingly, the results showed that acute coronary syndrome (ACS) patients had decreased plasma citric acid, 4-hydroxyproline (4OH-Pro), aspartic acid, and fructose; and increased lactate, urea, glucose, and valine [19]. Though the clear cross-talk of those changes to ACS needs to be further studied, the decrease in plasma 4OH-Pro was especially interesting because circulating 4OH-Pro is thought to prevent the binding of LDL to lipoprotein previously deposited in the vascular wall, as well as releasing already-deposited LDL from therosclerotic lesions. Furthermore, 4OH-Pro is a component of collagen, which also confers stability to the atherosclerotic plaque in the vessels.

In a similar study [20], the investigators applied both GC-MS and ^{1}H-NMR to investigate the plasma of patients with stable carotid atherosclerosis in comparison to that of healthy subjects. The results showed that these techniques complement each other and enable a clearer picture of the biological samples to be interpreted not only for classification purposes, but also more importantly to define the metabolic state of patients with carotid atherosclerosis. The metabolomic profiles showed at least 24 metabolites that were significantly modified in the group of atherosclerotic patients by this "nontargeted" procedure. Those metabolites include, but not exclusively, increased D-glucose, and decreased D-fructose, pyruvate (pyr) and

myoinositol (myo) which are involved in impaired insulin sensitivity, glycolysis, and glycogenesis; increased 3-OH—butyrate (3HB), acetoacetate (AcAc), long chain-fatty acids (such as palmitate, stearate, 11-transoctadecenoate, and linoleate), D-glycerol (gol), and decreased medium-chain fatty acids (hexanoate and laurate) produced from increased lipolysis and decreased lipogenesis, β-oxidation of fatty acids and deficient insulin signaling. In addition, increased 2-hydroxybutyrate was also found in this study, of which the increase was believed due to decreased L-threonine. Since most of the changes are associated to alterations of the metabolism characteristics of insulin resistance, the metabolic profiling in carotid atherosclerosis can be strongly related to metabolic syndrome. In summary, these studies highlight two important points. First, GC-MS and ^{1}H NMR fingerprints can provide complementary information in the identification of altered metabolic pathways in patients with carotid atherosclerosis. Second, correlations among results from both techniques, instead of a single study, can provide a deep insight into the patient state.

A number of laboratories have applied metabolomics to understand the progression of atherosclerosis in the apolipoprotein E (ApoE)*3Leiden mouse or the atherogenic ApoE gene knock-out (ApoE[-/-]) mouse model [21, 22]. In the ApoE3-Leiden (APO*E3) transgenic mice, which develop only mild type I and II atherosclerotic lesions, there are significant increases in liver-type fatty acid binding protein (L-FABP), in triglycerides, and selected bioactive lysophosphatidylcholine compared to controls, indicating a rapid identification of early protein and metabolite markers of disease pathology of this model. A correlation analysis of identified genes, proteins, and lipids was used to construct an interaction network, though some identified changes needed to be "translated" into human disease. Taken together, these results indicate that integrative biology is a powerful tool for rapid identification of early markers and key components of pathophysiological processes, and constitute the first application of this approach to a mammalian system [21]. Furthermore, the metabolic profiles fulfilled with LC-MS/MS also revealed that 1-Cys peroxiredoxin (1-cyc prx), a novel antioxidant conferring protection against oxidative membrane damage, was predominantly present as reduced protein in apolipoprotein E[+/+] vessels but is oxidized in apolipoprotein E[-/-] vessels [22], indicating that increased oxidative stress plays an important role in the development of atherosclerosis in this model. To identify the changes of protein and metabolite in the vessels of ApoE[-/-] mice on normal chow diet using proteomic and metabolomic technologies [22], investigators analyzed and mapped the protein expression in aortic smooth muscle cell (SMC)s of mice using two-dimensional gel electrophoresis (2-DE), matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) and LC-MS/MS [23]. In this study, 79 protein species were identified, of which the expression levels were increased during various stages of atherogenesis. Immunoglobulin deposition, redox imbalance, and impaired energy metabolism were found to precede lesion formation in ApoE[-/-] mice. Meanwhile, NMR revealed a decline in alanine and a depletion of the adenosine nucleotide pool in vessels of 10-week-old ApoE[-/-] mice. Furthermore, attenuation of lesion formation was associated with alterations of NADPH generating malic enzyme, which provides reducing equivalents for lipid synthesis and glutathione recycling, and successful replenishment of the vascular energy pool [23]. Given that increased dietary cholesterol is associated with atherogenesis in man and mouse, in a combined transcriptomics and metabolomic study, investigators [24] used novel whole-genome and HPLC/MS-based metabolome technologies to investigate the proinflammatory components of atherosclerosis that originate in livers of the groups of ApoE*3Leiden mice fed with cholesterol-free (control), low cholesterol (LC; 0.25%), and high cholesterol (HC; 1%) diets. The results showed that induced atherosclerosis was proportional to dietary intake of cholesterol because HC stress significantly activated specific proinflammatory pathways that is the platelet-derived growth factor (PDGF), interferon-γ (IFNγ), interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) signaling pathways. Activation of these proinflammatory pathways with HC treatment leads to a significant up-regulation of regulators, such as mitogen-activated protein kinases (MAP kinases), complement factors, and acute phase proteins such as serum amyloid A (SAA). Notably, several of these regulators control both lipid metabolism and inflammation, which suggests that the high-cholesterol diet not only induces inflammation but also alters lipid metabolism, thereby linking the dyslipidemia and inflammation with the early lesion formation of atherogenesis with this animal model Apparently, the study demonstrated that the combination of transcriptomics and metabolomics is a newly developed, functional systems biology tool, which allows for better definition of the perturbations associated with a given dietary intervention and to identify the novel regulatory pathways and transcriptional regulators controlling both lipid metabolism and inflammatory responses.

Applications of metabolomics in diabetes and obesity
The development of T2DM and obesity are highly correlated with uptake of the high fat diet. These disorders result in a number of metabolic perturbations including imbalance of glucose metabolism and dyslipidemia in key organs and blood plasma. These alterations lead to changes in the proportions of very low density lipoprotein (VLDL)/low density lipoprotein (LDL) to high density lipoprotein (HDL) and induce atherosclerosis. The disorders interact to produce what has been referred to as a Metabolic Syndrome whereby a number of separate risk factors for atherosclerosis interact to greatly magnify the risk of developing cardiovascular disease. Thus, metabolic changes are central to these disorders, and we would expect that any process aimed at measuring global metabolism changes would provide a good description of the phenotype of these diseases. Therefore, metabolomics has been used to identify the potential new disease markers of diabetes and obesity. In one study, LC-MS followed by multivariate statistical analysis was successfully applied to the metabolic profiling of plasma phospholipids in T2DM. The specific phospholipid molecular species, such as Glycerylphosphorylethanolamine (GPE), diacyl phosphatidyl ethanolamine, and lysophosphatidylcholine (Lyso-PC C16:0 and C18:0), detected at m/z range from 480 to 788 on LC-MS were identified as potential biomarkers for classifying the DM2 patients from the controls. With this methodology, it was possible not only to differentiate the T2DM from the controls but also to identify the potential

biomarkers with LC-MS/MS. The proposed method shows that LC-MS combined with multivariate statistical analysis is a complement or an alternative to NMR for metabolomics applications [7]. In the Insulin Resistance Atherosclerosis Study (IRAS), in which lipoprotein particles were measured using NMR, the investigator showed that a range of lipoprotein abnormalities in prediabetic individuals, including compositional changes in HDL (decreased) and VLDL (increased). These findings extend previous work indicating a proatherogenic state in healthy, nondiabetic subjects who subsequently develop diabetes [8], revealing that declines in glycerol and leucine/isoleucine (markers of lipolysis and proteolysis, respectively) jointly provide a predictor of insulin sensitivity [27, 28]. In a clinical study with type 1 diabetic (T1D) humans, MS revealed significant perturbations in the levels of plasma amino acids and amino acid metabolites during insulin deprivation as well as several metabolic pathways like protein synthesis and breakdown, gluconeogenesis, ketogenesis, amino acid oxidation, mitochondrial bioenergetics, and oxidative stress are also perturbed [29]. An ultra-performance LC quadruple–time of flight mass spectrometry (UPLC-q-TOF-MS)-driven non-targeted metabonomics study showed considerable changes of metabolite fingerprints in pre-diabetes, including increases in fatty acid- (FFAs C18:2, C16:1, C20:4 and C22:4; saturated FFA palmitate and FFA stearate, unsaturated FFA Oleate) and in glycochenodeoxycholic acid; and decrease in Lyso-PC- metabolism, uric acid, as well as tricarboxylic acid cycle -metabolism (TCA cycle) [30]. In another clinical study using targeted LC-MS profiling of blood plasma, investigators aimed to investigate whether metabolite profiles could predict the development of diabetes. The results showed a highly significant association between the levels of five branched chain and aromatic amino acids isoleucine, leucine, valine, tyrosine, and phenylalanine and the probability of future onset of diabetes. A combination of three amino acids predicted future diabetes (with a more than fivefold higher risk for individuals in top quartile). The results were later replicated in an independent, prospective cohort. These findings underscore the key role of amino acid metabolism early in the pathogenesis of diabetes and suggest that amino acid profiles could aid in diabetes risk assessment [31]. Furthermore, examination of plasma esterified fatty acids (EFAs) and non-esterified fatty acids (NEFAs) metabolic profiling using GC-MS indicated that most of the arachidonic acids (the class of C20 FAs) had significantly distinguishing characteristics in pathological progression. Most likely, because arachidonic acids are involved in in the anabolism of prostaglandins, these molecules are important modulators of inflammatory processes. Besides, most of the plasma EFA concentrations were reduced in DM cases when compared with control group, while NEFAs increased significantly. The EFA level fluctuation was suspected to be related with the cellular self-repair mechanism and NEFA variation resulting from EFAs self-adjusting mechanism. These findings could indicate potential biomarkers for monitoring the progression of DM as well as diabetic nephropathy (DN).

Potential mechanisms and the signalling pathways underlying the metabolite profiling changes associated with atherosclerosis, diabetes, and obesity
The mechanisms associated with accelerated atherosclerosis

development seen with the insulin resistance-associated conditions like T2DM and obesity are still under investigation, but it is believed that a decline in the bioavailability of nitric oxide (NO) and an increase in reactive oxygen species (ROS) are the most crucial factors. NO has the functions of vasorelaxant, anti-inflammatory, antiproliferative, antioxidant, and antiplatelet actions, demonstrating a crucial role in preventing endothelial dysfunction. The decline in the bioavailability of NO occurs as a result of reduced biosynthesis of NO and/or increased degradation by ROS. Several pieces of evidence have shown that impaired NO-dependent vasodilatation can predict future cardiac events and the development of coronary artery disease. A range of studies have provided compelling evidence supporting a strong association between obesity, insulin resistance, and NO bioavailability. Furthermore, in a diet-induced model of obesity the data has shown that insulin-mediated NO release is blunted in the early development of obesity, which is believed to be associated with increased endothelial cell-derived ROS. This finding was supported by a study in a non-obese model of whole body insulin resistance, where reduced basal and insulin-mediated NO release was demonstrated, as a result of increased endothelial cell nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived ROS from vascular oxidative stress. Oxidative stress is thought to play a pivotal role in the pathophysiology of atherosclerosis, and insulin resistance. A prevailing theory is that increased delivery of lipids to muscle tissues saturates the capacity for mitochondrial ß-oxidation, leading to accumulation of bioactive lipid-derived metabolites such as diacylglycerols and ceramides in the extra mitochondrial space and the activation of stress/serine kinases that interfere with insulin action. More recent studies have shown that fatty acid oxidation is actually increased in muscle tissues in response to high-fat feeding, but with no corresponding increase in TCA cycle activity. This results in accumulation of incompletely oxidized lipids in the mitochondria and depletion of TCA cycle intermediates, possibly resulting in mitochondrial stress and interference with insulin actions.
ROS are thought to promote atherosclerosis through a number of different mechanisms including enhanced oxidation of lipoproteins, activation of pro-inflammatory genes, alteration of vascular smooth muscle cell phenotype, and possibly most importantly, reduction of NO bioavailability. ROS in the arterial wall are generated by several enzymes including NADPH oxidase, xanthine dehydrogenase; cytochrome p450 based enzymes, the mitochondrial electron transfer chain, as well as infiltrating inflammatory cells. Moreover, NADPH oxidase-derived ROS can impact the major cellular sources of ROS, the mitochondria, to enhance superoxide production from this organelle. As a result of this complex interplay between sources of ROS, a self-propagating cycle can ensue, amplifying endothelial ROS production, reducing NO bioavailability and generating an increasingly proatherosclerotic environment. As discussed above, mitochondrial electron transport is one of the major producers of ROS. It was believed that uncoupling protein 1 (UCP-1) in vascular smooth muscle cells plays an important role in ROS production and atherosclerosis. The study in Semenkovich's laboratory demonstrated that UCP-1 generated ROS from vascular smooth muscle cells leads to elevated ROS, reduced NO bioavailability and accelerated

atherosclerosis in mice on an ApoE deficient background. In contrast, overexpression of UCP-1 in the endothelium was shown to blunt free fatty acid (FFAs)-induced ROS production, suggesting that overexpression of UCP-1 in the endothelium may protect against endothelium cell dysfunction. The controversy warrants future studies. In addition to vascular smooth muscle cells, the role of mitochondrial dysfunction and ROS production in the endothelium during diabetic and obesity states has been extensively examined. It is believed that free fatty acids at pathophysiological concentrations increases ROS production in macrovascular endothelial cells through increased expression of NADPH oxidase-p47 (phox) and endothelial oxidative stress, with selective compensatory upregulation of antioxidant enzymes and Ser1177-phosphorylated endothelial nitric oxide synthase (eNOS). Consistent with findings in humans, NADPH oxidase has been shown to be a key sources of ROS in adipose tissue of obese mice. Of note, endothelial cell NADPH oxidase is thought to be the principal source of reduced NO bioavailability and significant vascular oxidative stress in insulin resistance.

Recently, NADPH oxidase has emerged as a major source of superoxide in obese humans, those with metabolic syndrome, patients with T2D, and those with chronic heart failure. Endothelin-1 and nuclear factor-kappaB protein expression also appear to be elevated in obese adults, suggesting a novel insight into the molecular mechanisms linking obesity to increased risk of clinical atherosclerotic diseases in humans.

It is well established that obesity and T2DM are associated with proatherogenic dyslipidemia, which is characterized as an increase in plasma triglycerides and FFAs, a reduction in HDL, and the presence of small, susceptible LDL particles. A significant event in the early progression of atherosclerosis is the permeation of small LDL particles across the endothelial barrier and its subsequent accumulation in the vascular wall. The discrete steps in triglyceride and FFAs handling increases ROS production and activates NADPH oxidase and mitochondrial electron chain to generate superoxide. The excessive ROS production from one source can lead to enhanced production of ROS from another. Phospholipids contained within LDLs are highly susceptible to oxidation by ROS leading to the generation of oxidized phospholipids (OxPLs). OxPLs formation triggers endothelial cell activation, facilitating monocyte adhesion and stimulating expression of inflammatory cytokines. Aside from this, elevated FFA itself may also have direct effects on NO biosynthesis and impair mitochondrial uncoupling. In insulin-resistant murine models, FFA-induced ROS production substantially inhibited prostacyclin synthase and eNOS activity in aorta. The interlocking effects of FFA on insulin resistance and ROS may lead to a vicious cycle of lipotoxicity-induced vascular dysfunction. Activation of the transcription factor NF-kB signaling pathway and inflammatory mediator toll-like receptor-4 (TLR4) signaling via the serine kinase inhibitor kappaB kinase B (IKKB) activation may disrupt insulin signaling via inhibition of insulin receptor substrate 1, Akt (protein kinase B), and eNOS phosphorylation. In turn, this leads to a decrease in NO production, perhaps instigating inflammation and endothelial dysfunction.

Conclusions
In summary, as a research tool, metabolomics has been successfully applied to the research of disorders such as atherosclerosis, diabetes, and obesity. This technology has been applied to the identification of novel biomarkers not only for the diagnosis of diseases, but also for the assessment of severity and provision of prognostic information in these conditions. An emerging set of metabolomics tools like MS, NMR, and other technologies enable the monitoring of metabolite profiles from biological samples of these disorders that has provided certain advantages relative to other "omics" technologies like genomics, transcriptomics, and proteomics. Since it measures chemical phenotypes that are the net result of genomic, transcriptomics, and proteomic variability, metabolomics provides the most integrated profile of biological status. However, metabolomics is still a field in its infancy, with some limitations and difficulties and even confusions in the interpretation of its data. In contrast, Genome-wide association studies and mRNA profiling by microarray analysis are relatively mature technologies. Though metabolomics technologies are still under development, they complement other functional "omics" approaches, such as high throughput genome sequencing, RNA expression analysis, and proteomics. Metabolomics promises to be invaluable in illuminating systems biology, the discovery of biomarkers for disease diagnosis, and treatment assessment. Metabolomic studies to date have identified quite diversified metabolites in blood, tissues, and urine in the process of atherosclerosis, diabetes, and obesity, of which most are the intermediates of specific lipid classes, fatty acids, carbohydrates, amino acids, bile acids, purine, pyrimidine, and proteins. The identified metabolites and their sources and/or related mechanisms with atherosclerosis, diabetes and obesity are summarized. Accumulations of the metabolomic datasets in these studies led us to the mechanism that decreased NO bioavailability, increased ROS production and mitochondria dysfunctions play crucial roles in the production of metabolites associated with these disorders. These findings may narrow the focus of future metabolomic studies in understanding the mechanisms of atherosclerosis, diabetes, and obesity.

References
1. Goodacre R. Metabolic profiling: pathways in discovery. Drug Discov Today. 2004; 9:260-261. 10.1016/S1359-6446(04)03027-2
2. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 2004; 22:245-252. 10.1016/j.tibtech.2004.03.007
3. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998; 16:373-378. 10.1016/S0167-7799(98)01214-1
4. Scarfe GB, Wright B, Clayton E, Taylor S, Wilson ID, Lindon JC *et al*. 19 F-NMR and directly coupled HPLC-NMR-MS investigations into the metabolism of 2-bromo-4-trifluoromethylaniline in rat: a urinary excretion balance study without the use of radiolabelling. Xenobiotica. 1998; 28:373-388. 10.1080/004982598239489

5. Lindon JC, Holmes E, Nicholson JK. So what's the deal with metabonomics? Anal Chem. 2003; 75:384A-391A.
6. Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. 2012; 32:31-24.
7. Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S *et al*. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem. 2005; 77:4108-4116. 10.1021/ac0481001
8. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE *et al*. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation. 2005; 111:3465-3472. 10.1161/CIRCULATIONAHA.104.512079
9. Roberts LD, Murray AJ, Menassa D, Ashmore T, Nicholls AW, Griffin JL. The contrasting roles of PPARdelta and PPARgamma in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biol. 2011; 12(8):R75. 10.1186/gb-2011-12-8-r75
10. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI *et al*. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2004; 10:268-274. 10.1038/nm995
11. Wakelam MJ, Pettitt TR, Postle AD. Lipidomic analysis of signaling pathways. Methods Enzymol. 2007; 432:233–246.
12. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF *et al*. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009; 9:311-326. 10.1016/j.cmet.2009.02.002
13. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I *et al*. The human serum metabolome. PLoS One 2011; 6:e16957. 10.1371/journal.pone.0016957
14. Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J *et al*. A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics. 2006; 27:178-186. 10.1152/physiolgenomics.00060.2006
15. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R *et al*. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005; 112:3868-3875. 10.1161/CIRCULATIONAHA.105.569137
16. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW *et al*. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002; 8:1439-1444. 10.1038/nm1202-802
17. Brindle JT, Nicholson JK, Schofield PM, Grainger DJ, Holmes E. Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst. 2003, 128:32-36. 10.1039/b209155k
18. Kirschenlohr HL, Griffin JL, Clarke SC, Rhydwen R, Grace AA, Schofield PM *et al*. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med. 2006; 12:705-710. 10.1038/nm1432
19. Martinez-Pinna R, Barbas C, Blanco-Colio LM, Tunon J, Ramos-Mozo P, Lopez JA *et al*. Proteomic and metabolomic profiles in atherothrombotic vascular disease. Curr Atheroscler Rep. 2010; 12:202-208. 10.1007/s11883-010-0102-y
20. Teul J, Ruperez FJ, Garcia A, Vaysse J, Balayssac S, Gilard V *et al*. Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J Proteome Res. 2009; 8:5580-5589. 10.1021/pr900668v
21. Clish CB, Davidov E, Oresic M, Plasterer TN, Lavine G, Londo T *et al*. Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS. 2004; 8:3-13. 10.1089/153623104773547453
22. Mayr M, Chung YL, Mayr U, Yin X, Ly L, Troy H, *et al*. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol. 2005; 25:2135-2142. 10.1161/01.ATV.0000183928.25844.f6
23. Mayr U, Mayr M, Yin X, Begum S, Tarelli E, Wait R, *et al*. Proteomic dataset of mouse aortic smooth muscle cells. Proteomics. 2005; 5:4546-4557. 10.1002/pmic.200402045
24. Kleemann R, Verschuren L, Van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER *et al*. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 2007; 8:R200. 10.1186/gb-2007-8-9-r200
25. Leo GC, Darrow AL. NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice. Magn Reson Chem. 2009; 47(1):S20-25.
26. Zhang F, Jia Z, Gao P, Kong H, Li X, Chen J, Yang Q *et al*. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta 2009, 79: 836-844. 10.1016/j.talanta.2009.05.010
27. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS *et al*. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol. 2008, 4:214.
28. Lucio M, Fekete A, Weigert C, Wagele B, Zhao X, Chen J *et al*. Insulin sensitivity is reflected by characteristic metabolic fingerprints--a Fourier transform mass spectrometric non-targeted metabolomics approach. PLoS One. 2010; 5:e13317. 10.1371/journal.pone.0013317
29. Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 2010; 5:e10538. 10.1371/journal.pone.0010538
30. Zhao X, Fritsche J, Wang J, Chen J, Rittig K, Schmitt-Kopplin P *et al*. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics. 2010; 6:362-374. 10.1007/s11306-010-0203-1.